Related Experiment Video

Updated: Jul 7, 2026

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

Eicosanoids and renal damage in cardiometabolic syndrome

John D Imig1

  • 1Vascular Biology Center, Medical College of Georgia, Augusta, GA 30912, USA. jdimig@mcg.edu

Expert Opinion on Drug Metabolism & Toxicology
|February 6, 2008
PubMed

Insights

Cardiometabolic syndrome damages kidneys through altered eicosanoids. Soluble epoxide hydrolase inhibitors offer potential therapeutic benefits for chronic kidney disease patients with this condition.

Area of Science:

  • Nephrology
  • Metabolic Diseases
  • Cardiovascular Health

Background:

  • Obesity, hypertension, and Type 2 diabetes drive chronic kidney disease.
  • Cardiometabolic syndrome involves visceral obesity, cardiovascular risks, and systemic inflammation.
  • Inflammation, insulin resistance, and endothelial dysfunction are interconnected, linking metabolic and cardiovascular diseases.

Purpose of the Study:

  • To review the role of eicosanoids in kidney damage within cardiometabolic syndrome.
  • To explore therapeutic targets for protecting kidneys in this patient population.

Main Methods:

  • Literature review of eicosanoid involvement in cardiometabolic syndrome and renal injury.
  • Analysis of the relationship between inflammation, endothelial dysfunction, and insulin resistance.
  • Evaluation of potential therapeutic strategies targeting eicosanoid pathways.

Main Results:

  • Eicosanoid metabolism is significantly altered in cardiometabolic syndrome.
  • These alterations contribute to the progression of renal damage.
  • Epoxides and soluble epoxide hydrolase inhibitors exhibit antihypertensive and anti-inflammatory effects.

Conclusions:

  • Altered eicosanoids are key contributors to kidney injury in cardiometabolic syndrome.
  • Epoxides and soluble epoxide hydrolase inhibitors represent promising therapeutic targets.
  • Targeting eicosanoids may offer renal protection for patients with cardiometabolic syndrome and chronic kidney disease.
Abstract

More Related Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...